light blue DNA strands

    Microsatellite stability biomarker (MSS) and colorectal cancer

    light blue DNA strands
    magnifying glass finds light behind trees

    What is an MSS biomarker?

    MSI (microsatellite instability) and MSS (microsatellite stability) biomarkers indicate how stable the DNA is in a tumor.

    If a cell’s DNA is unstable, particles called microsatellites are produced. Colorectal cancer tumors are often referred to as having an “MSI status,” meaning they are described as either MSI or MSS. They cannot be both.

    An MSS (microsatellite stability) result indicates that the DNA in the cells are considered stable. If there is a lot of instability in the DNA, it is described as MSI-H (microsatellite instability high).

    woman sitting in doctor's office

    How common is MSS?

    • Approximately 80-85 percent of colorectal cancer patients are classified as MSS, with a functional MMR process and no mutations in their MMR genes.
    • Approximately 15 percent of colorectal patients have dMMR and areMSI-H.
    • In three to five percent of colorectal patients, dMMR and MSI-H are caused by Lynch syndrome. In these patients, a hereditary mutation (germline mutation) in one of the four main MMR genes is passed from one generation to another in a family. Individuals with Lynch syndrome are at higher risk of developing colorectal, endometrial (uterine), gastric, ovarian, and other cancers.
    • Lynch syndrome
    Asian elder woman sits in hospital bed

    Who should have MSS testing?

    MSS testing is recommended for anyone who is diagnosed with colorectal cancer.

    female doctor writes a report

    What happens if I have an MSS biomarker?

    Knowing the details of tumor biomarkers can help you and your doctor make decisions about personalized treatment with therapies tailored specifically to the characteristics of your tumor.

    Patients diagnosed with an MSS tumor have a higher risk of recurrence. If you have stage IV (metastatic) colorectal cancer, your doctor will test for additional biomarkers including KRAS/NRAS, BRAF, andHER2. 

    liquid meds on a laboratory shelf

    What treatment options are available?

    Patients with MSS tumors are treated with fluorouracil-based chemotherapy or similar drugs.

    Currently, pembrolizumab has been approved for some MSS tumors. There are ongoing clinical trials for immunotherapy in combination with different drugs for for MSS patients.

    Asian female in a wheelchair with a headache

    What are the potential side effects of treatment?

    Some of the most common side effects of treatment for patients with MSS tumors are nausea, fatigue, diarrhea or constipation, headaches, and high temperature.

    It is unlikely that you will have all of these side effects, but you might have some of them. Contact your doctor immediately if you are experiencing severe symptoms.

    Top resources

    View all resources
    A close-up digital illustration of glowing blue DNA strands twisting through a dark blue background. Multiple double helixes appear at different depths, connected by a network of lighted nodes and lines.

    A blood test that sees what scans can't

    For many cancer patients, the end of active treatment brings a new kind of dread. Scans every few months and anxious waits for results. A blood test is changing that experience for a growing number of patients.

    Last updated
    A collage featuring a smiling woman with a chest infusion port, a medical team preparing for a procedure, and a close-up of an HAI pump used for liver-directed chemotherapy treatment.

    HAI therapy proves pivotal for pioneering patient

    When Helen was diagnosed with metastatic colorectal cancer, the biggest concern for her medical team was that her cancer had spread to her liver. One type of therapy, hepatic artery infusion, offered a path forward, but there was a catch. Nobody at her hospital had ever done it before. She'd have to be first.

    Last updated